LeonaBio, Inc.

LONA

Healthcare|Biotechnology|US

$4.42

+0.07 (+1.73%)

DCF Value

$15.07

Tangible Book / Share

$7.86

Cash / Share

$11.94

Clinical Trials (9)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT05696626 Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation	Metastatic Breast Cancer	P3	Recruiting	600	RCT, Open-label	Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
NCT04488419 ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease	Alzheimer Disease, Dementia of Alzheimer Type	P2P3	Completed	554	RCT, Double-blind	ATH-1017, Placebo
NCT04886063 Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease	Alzheimer Disease	P2P3	Terminated	423	Open-label	ATH-1017
NCT04831281 ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)	Parkinson Disease Dementia, Dementia With Lewy Bodies	P2	Terminated	28	RCT, Double-blind	ATH-1017, Placebo
NCT04491006 A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease	Alzheimer Disease, Dementia of Alzheimer Type	P2	Completed	77	RCT, Double-blind	ATH-1017, Placebo
NCT06432647 A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-1105	Healthy Volunteers	P1	Completed	80	RCT, Double-blind	ATH-1105, Placebo
NCT05169671 Safety, Tolerability, and Pharmacokinetics Study of ATH-1020	Healthy Volunteers	P1	Completed	32	RCT, Double-blind	ATH-1020, Placebo
NCT03298672 Safety, Tolerability, and Pharmacokinetics Study of NDX-1017	Alzheimer Disease	P1	Completed	88	RCT, Double-blind	NDX-1017, Placebo
NCT05511558 A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017)	Healthy Volunteers	P1	Completed	8	Open-label	[14C]-Fosgonimeton